Skip to main content

nevirapine (Viramune®)

 

Following a limited submission

AWMSG advice

Status: Recommended

Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets. Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used. Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing.

 Final Recommendation: nevirapine (Viramune) 1581 (PDF, 340Kb)
 Appraisal Report: nevirapine (Viramune) 1581 (PDF, 240Kb)

Medicine details

Medicine name nevirapine (Viramune®)
Formulation 50 mg prolonged-release tablet, 100 mg prolonged-release tablet, 400 mg prolonged-release tablet
Reference number 1581
Indication

In combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets.  Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine.  Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.  Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs).  The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing

Company Boehringer Ingelheim Ltd
BNF chapter Infections
Submission type Limited
Status Recommended
Advice number 1612
NMG meeting date 15/05/2012
AWMSG meeting date 20/06/2012
Ratification by Welsh Government 23/07/2012
Date of issue 27/07/2012
Date of last review December 2022
Further information

This appraisal recommendation was reviewed in December 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations

Scrutiny Panel meeting date useMuraDefault
LOWMAG meeting date useMuraDefault
OWMAG meeting date useMuraDefault
Follow AWTTC: